Source: Zolmax News

Myovant Sciences: Myovant Sciences (NYSE:MYOV) Price Target Raised to $29.00 at SVB Leerink

Myovant Sciences (NYSE:MYOV) had its price objective lifted by equities research analysts at SVB Leerink from $27.00 to $29.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The brokerage presently has an "outperform" rating on the stock. SVB Leerink's price objective would suggest a potential upside of 46.98% from the [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating


Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more